CB-7 exhibits a weak TLR7 inhibiting effect in normal mice. The present invention provides a novel compound with a stronger TLR7 inhibiting effect than CB-7, a pharmaceutically acceptable salt of said compound, or a prodrug of said compound or salt. The present invention also provides a drug for the prevention or treatment of diseases associated with the activation of TLR7, said drug including the aforementioned TLR7 activation inhibitor.

The present disclosure relates to populations of small pluripotent stem cells derived from peripheral blood, such as human peripheral blood. In some aspects, these small pluripotent stem cells are smaller than known stem cells and express a range of embryonic, hematopoietic, or mesenchymal stem cell markers. Also disclosed herein are methods of isolation and cryopreservation of these populations of small pluripotent stem cells. These small pluripotent stem cells may be differentiated in a wide range of cell types, which can be used in various applications such as the study of cell activity or for treatment of diseases and personalized medicine.

Primarily aimed at providing a novel pharmaceutical composition. The present invention relates to a pharmaceutical composition that contains a cerium compound as an active ingredient.

Primarily aimed at providing a novel pharmaceutical composition. The present invention relates to a pharmaceutical composition that contains a cerium compound as an active ingredient.

Disclosed are an IL-5 binding molecule, and a preparation method and use thereof. The binding molecule includes the following complementarity determining regions: an amino acid sequence of CDR1 selected from any one of sequences as set forth in SEQ ID NOs. 43-49; an amino acid sequence of CDR2 selected from any one of sequences as set forth in SEQ ID NOs. 50-56; and an amino acid sequence of CDR3 selected from any one of sequences as set forth in SEQ ID NOs. 57-62. The binding molecule is capable of specifically binding to IL-5, and effectively blocking the cell proliferation induced by IL-5.

The present technology relates to methods comprising the administration of methotrexate and glucarpidase to treat central nervous system lymphoma in a subject in need thereof. Kits for use in practicing the methods are also provided.

The present invention provides a compound suitable for use as an acetyl CoA carboxylase (ACC) inhibitor, specifically, a thienopyridine derivative, and use of the compound in the preparation of drugs for treating metabolic disorders, cancers or other proliferative disorders, and nonalcoholic steatohepatitis (NASH).

Provided herein are methods of treating heart failure, chronic kidney disease (CKD) or hypertension, in a companion animal, comprising administering to a companion animal in need thereof a therapeutically effective amount of a compound that inhibits a sodium-dependent glucose transporter (SGLT) or a prodrug thereof. In some embodiments, the compound that inhibits an SGLT is bexagliflozin.

Provided herein are methods of treating heart failure, chronic kidney disease (CKD) or hypertension, in a companion animal, comprising administering to a companion animal in need thereof a therapeutically effective amount of a compound that inhibits a sodium-dependent glucose transporter (SGLT) or a prodrug thereof. In some embodiments, the compound that inhibits an SGLT is bexagliflozin.

An amorphous form of a nitrogen-containing tricyclic compound and a use thereof, a pharmaceutical composition containing the compound in the amorphous form, and the use of the compound in the amorphous form or the pharmaceutical composition in the preparation of a drug for preventing, treating or alleviating FXR-mediated diseases in a patient.